Panaxia

Executive Summary

Panaxia is an Israeli pharmaceutical company specializing in GMP-certified medical cannabis products, including sublingual tablets, vaporized extracts, and suppositories. Founded in 2020 and headquartered in Tel Aviv, the company leverages advanced extraction, standardization, and delivery technologies to produce consistent, high-quality cannabinoid therapies for pain management, neurology, and oncology supportive care. With $10 million in total funding and a commercial-stage classification, Panaxia targets the rapidly expanding global medical cannabis market, estimated to reach $56 billion by 2030. The company's proprietary platform ensures precise dosing and bioavailability, addressing key challenges in the industry and positioning it for partnerships with healthcare providers and pharmaceutical distributors. Panaxia's commercial operations are supported by a GMP-certified manufacturing facility, enabling it to supply standardized products to both domestic and international markets. The company's strategic focus on developing novel delivery formats, such as sublingual tablets that bypass first-pass metabolism, differentiates it from competitors offering oils or dried flower. While the medical cannabis sector faces regulatory hurdles, Panaxia's compliance with stringent quality standards fosters trust among physicians and patients. The company's private status and absence of a public ticker limit immediate liquidity opportunities, but its technology and product pipeline could attract acquisition interest from larger pharmaceutical firms seeking to enter the cannabinoid space.

Upcoming Catalysts (preview)

• Q1 2027Publication of Phase 2 clinical trial results for sublingual tablet in chronic pain70% success
• Q3 2026Receipt of EU-GMP certification for expanded manufacturing capacity85% success
• Q4 2026Strategic partnership with a top-20 pharmaceutical company for European distribution40% success